Knowledge Library

Platform Supporting the Discovery of Agents against HSV

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are globally prevalent human pathogens associated with a wide range of diseases, from mild conditions such as herpes labialis (cold sores) to serious infections such as encephalitis and meningitis. HSV can establish a lifelong latent infection in neurons of the peripheral nervous system and can reactivate …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Cell-based Assays, in vivo Pharmacology, Infectious Diseases

VIEW

Asthma Services Platform

Asthma is a chronic, lower airway disease characterized by persistent inflammation and hyperreactivity. Asthma involves a complex immune response, with T-helper 2 (Th2) cells playing a central role, leading to activation of eosinophils and increased levels of IgE antibodies. Clinically, airflow obstruction in asthma often is not fully reversible, and many asthmatic subjects experience an …Read More >

Resource Type: Presentation
Resource Topic: Cell-based Assays, in vivo Pharmacology, Respiratory Diseases

VIEW

USP7 Inhibitors Reveal a Differentiated Mechanism of p53-Driven Anti-Cancer Activity

Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that cleaves ubiquitin from a range of substrates, shielding them from degradation by the proteasome. USP7 activity has been implicated in cancer progression and its overexpression is associated with tumor aggressiveness and poor prognosis in a variety of cancer types, making USP7 inhibition an attractive strategy for …Read More >

Resource Type: Latest Science, Publication
Resource Topic: Cell-based Assays, Oncology, Structural Biology, Targeted Protein Degradation, Tumor Models

VIEW

Creating a Biological Switch Using DEL Technology

In addition to identifying chemical starting points for early drug discovery processes, DNA-encoded library (DEL) technology has now expanded to new applications, including the discovery of bifunctional affinity ligands historically considered difficult to develop. At the 2024 Gordon Research Conference, WuXi AppTec presented a poster describing how DEL can enable the rapid discovery of novel …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Biochemical Assays, CAR-T Cell, Cell-based Assays, DNA-Encoded Library (DEL), Hit Finding

VIEW

iMN041: Prodrug with a Unique Antitumor Immune Response

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses generated by iMN041, a prodrug of a DNA methyl transferase/ribonucleotide reductase inhibitor.  This study also assessed the efficacy of iMN041 in mouse xenografts of human clear cell renal cell cancer, pancreatic cancer, and triple negative …Read More >

Resource Type: Latest Science, Publication
Resource Topic: Cell-based Assays, Immunology, Oncology, Tumor Models

VIEW

Expanded Applications of PDX Models

Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease. WuXi AppTec offers a comprehensive platform of more than 1,400 well-annotated PDXs across 30 cancer types. We also provide expanded in vitro, ex …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Cell-based Assays, Oncology, Tumor Models

VIEW

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held this year in San Diego, CA, USA. As one of the most influential international conferences dedicated to cancer immunotherapy, SITC provides attendees with a cross-disciplinary educational and interactive platform. This meeting focuses on discussing and …Read More >

Resource Type: Article, Blog
Resource Topic: Antibodies, Autoimmune and Inflammatory Diseases, Cell-based Assays, in vivo Pharmacology, Oligonucleotides, Oncology

VIEW

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Antibodies, Cell-based Assays, Oligonucleotides, Oncology, Tumor Models

VIEW

Upregulation of drug metabolism enzymes mediates ADC resistance in a HER2-positive cancer cell line

SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant non-small cell lung cancer. However, despite Enhertu’s clinical benefits, most patients inevitably experience disease progression and mortality. Understanding drug resistance mechanisms can aid in developing new treatment strategies for drug-resistant clinical patients. In this study, …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Cell-based Assays, Oncology

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!